ADC Therapeutics taps Novartis vet Ameet Mallik as its next CEO, replacing co-founder Martinnews2022-05-09T13:27:41+00:00May 9th, 2022|Fierce Pharma|
UPDATED: Seagen CEO Clay Siegall put on leave after domestic violence arrestnews2022-05-09T12:33:59+00:00May 9th, 2022|Fierce Pharma|
Idorsia’s insomnia drug Quviviq hits the market with 500 sales reps and plans for ‘robust’ DTC campaignnews2022-05-07T21:09:33+00:00May 7th, 2022|Fierce Pharma|
After 2 years, Sanofi’s drug ingredients spinoff takes flightnews2022-05-06T13:59:30+00:00May 6th, 2022|Fierce Pharma|
AstraZeneca, GSK’s cancer rival Clovis quietly unveils crippling FDA delay as its troubles deepennews2022-05-06T13:42:39+00:00May 6th, 2022|Fierce Pharma|
Back where it started: FDA restricts use of J&J’s COVID-19 shot because of blood clot threatnews2022-05-06T13:16:09+00:00May 6th, 2022|Fierce Pharma|
Gerresheimer invests in Portal’s needle-free drug delivery, teeing Takeda partner up to advance technews2022-05-06T13:09:21+00:00May 6th, 2022|Fierce Pharma|
Vertex, riding high on Trikafta, isn’t just a rare disease company, execs saynews2022-05-06T11:57:10+00:00May 6th, 2022|Fierce Pharma|
Fierce Pharma Asia—Enhertu’s breast cancer nod; Biogen, Eisai’s next play; FDA snubs 2 China-made cancer drugsnews2022-05-06T11:39:22+00:00May 6th, 2022|Fierce Pharma|
Intra-Cellular sees the ‘hope and the light’ as it kick-starts new Caplyta bipolar campaignnews2022-05-06T10:02:16+00:00May 6th, 2022|Fierce Pharma|
